top of page
  • X
  • LinkedIn

Advancing neuroscience. Expanding treatment possibilities.

DISCOVER THE FUTURE OF CNS THERAPEUTICS

Neuroscience With a Clear Purpose

We develop next-generation therapeutics for serious central nervous system conditions where effective treatments remain a critical unmet need. By combining neuroscience research with medicinal chemistry and pharmaceutical development expertise, we aim to translate promising science into practical medicines that improve patients’ lives.

Doctor analyzing brain scans
Image by Jose Antonio Rodriguez Davia

A Pipeline Built Around Unmet Need

Our pipeline includes EQL-101, an ibogaine-inspired preclinical program, and TRH-NP, an intranasal nanoparticle program being developed for potential rapid CNS intervention. Our serotonin-releaser discovery platform supports the exploration of future CNS candidates.

​

We connect clinical research and medicinal chemistry with the pharmaceutical expertise needed to advance these programs toward clinical development. Each follows its own development pathway, guided by scientific evidence and regulatory requirements.

Equulus
Equulus Research

1

EQL-101

Substance Use Disorders; PTSD

  • EQL-101 is an ibogaine-inspired preclinical program that aims to preserve the therapeutic potential of ibogaine-related pharmacology while reducing cardiac risk and avoiding hallucinogenic effects. The program targets substance use disorders, with PTSD as a potential additional indication. Medicinal chemistry, pharmacology, pharmacokinetics and safety assessment guide its development.

2

EQL-988

Rapid CNS Intervention

  • TRH-NP is an intranasal thyrotropin-releasing hormone nanoparticle program being developed for potential rapid CNS intervention. The program explores nanoparticle-based intranasal delivery as a therapeutic approach. Equulus is evaluating the lead clinical indication and planning the preclinical work required to support a new investigational new drug application.

Microscope Close-Up

3

SEROTONIN-RELEASER DISCOVERY PLATFORM

Target Indications Under Evaluation

  • Our discovery portfolio explores serotonin-releasing compounds as a source of potential future CNS candidates. MDMA-inspired and fenfluramine-class approaches remain distinct research directions within the portfolio. Compound-specific pharmacology and safety evaluation will guide candidate selection.

Our Purpose

Promising science. Practical medicines.

“Our ambition is to translate promising neuroscience into practical medicines that help people recover, restore function and reclaim their lives. We combine clinical research with pharmaceutical development expertise, building the evidence for each program while considering how future treatments can be delivered in everyday care.”

Robert P. Discordia, PhD

Co-Founder, President & Chief Executive Officer

Bob Discordia

Meet the Team

Robert Discordia brings more than 30 years of pharmaceutical and biotechnology experience to Equulus. His expertise spans end-to-end drug development, including deep experience in chemistry, manufacturing and controls (CMC). He has advanced programs from preclinical research through clinical development and commercialization across multiple therapeutic areas. At Equulus, he leads corporate strategy and pharmaceutical development, drawing on this experience to advance the pipeline toward clinical and commercial milestones.

030-nbk24PW8xmg.jpeg

Robert Discordia, PhD

Co-Founder, President &

Chief Executive Officer

Peter Hendricks is a clinical psychologist and the Heersink Endowed Professor in the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham. His research focuses on psychedelic-assisted therapies and patient outcomes, including substance use disorders. He has designed and led clinical trials of psychedelic-assisted therapies. At Equulus, he guides clinical research strategy and rigorous, patient-centered trial design, drawing on his leadership of these studies.

PSH2_edited.jpg

Peter Hendricks, PhD

Co-Founder, Director &

Chief Advisor on Clinical Psychology

Bruce Blough is a medicinal chemist with decades of experience in CNS drug discovery. His research at Research Triangle Institute helped establish the serotonin-releaser portfolio under evaluation by Equulus. He brings expertise in structure–activity relationships, scaffold design and intellectual-property strategy. At Equulus, he guides molecular design and candidate selection, helping translate discovery findings into candidates suitable for further development.

BLOUGHB.jpg

Bruce Blough, PhD

CCo-Founder, Director &

Chief Advisor on Medicinal Chemistry

Kevin Murnane is Associate Professor of Pharmacology, Toxicology & Neuroscience and of Psychiatry at LSU Health Shreveport, and Director of Basic Science Research at the Louisiana Addiction Research Center. A specialist in neuropharmacology and neurotoxicology, his research examines addiction and stimulant-induced brain injury. At Equulus, he guides preclinical efficacy models, mechanism assessment and the interpretation of pharmacology and safety findings to inform development decisions.

KMurnane_Heahshot-2024-04-02_1b_edited.jpg

Kevin Murnane, PhD

Co-Founder & Director, Neuropharmacology & Neurotoxicology

Drew Mouton, Co-Founder, Director and Chief Business Officer of Equulus Therapeutics, brings experience in corporate strategy, business development and capital formation. He has executed licensing transactions and strategic alliances, and structured dilutive and non-dilutive financings to advance development programs. At Equulus, he guides business development and financing strategy, building relationships that support the company’s CNS development priorities.

DM_Headshot_2024_1b.jpg

Drew Mouton, MBA, MGM

Co-Founder & Chief Business Officer

Copy of Equulus-29_edited.jpg

Meet the Advisory Board

rick shelton-april2017 white coat headshot uab resize 9-18-25.png

Dr. Richard Shelton

University of Alabama at Birmingham

BruceHeadShot.jpg

Dr. Bruce Car

Biohaven Pharmaceuticals, CSO

JJRenger.jpeg

Dr. John Renger

Principal, Neurtuitive, 

Former CSO, Cerevel

Perry.png

Pamela Perry

Former SVP, Cerevel Therapeutics

NNaito.jpg

Dr. Neal Naito

CEO, MVK Pharmaceuticals

Andrew Riley.jpeg

Dr. Andrew Riley

Assistant Professor of Pharmaceutical Sciences Medicinal Chemistry & Pharmacognosy at the University of Illinois Chicago

profile.jpeg

Angela Terhune Hargrove

Co-Founder, CSO at First Coast Research Center

Explore the Equulus Opportunity

Equulus Therapeutics is advancing breakthrough therapeutics for central nervous system (CNS) disorders using a transdiagnostic strategy rooted in disease-driving physiology—guided by an experienced neuroscience team and developed with strategic partners. Open the deck to explore our science, programs, and milestones.

Microscope_edited.jpg

Our Development Focus

SEROTONIN-RELEASER
DISCOVERY PLATFORM

Discovery Platform

EQL-101
TRH-NP (EQL-988):

Complementary CNS Development

OUR PARTNERS

Media

Rethinking Mental Health: How Emerging Therapies Are Changing the Game

Newsweek

Read More

Press

There’s a New Kid in Town, Changing the Face of Genetic Engineering.


March 2035

Investor Relations
ir@hlthcommunications.com

HLTH Communications Inc.

 

Media Inquiries
pr@hlthcommunications.com

HLTH Communications Inc.

Copy of Equulus-28.png

Connect With Equulus

Join The Equulus Newsletter

Be the first to receive the latest news and updates.

bottom of page